Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit
Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensusreuters.com. This was achieved on quarterly revenue of about $16.7 billion, which, while ~6% lower than the same period last year, slightly exceeded analysts’ forecastsstocktwits.comreuters.com. The decline was largely anticipated due to the sharp drop in COVID-19 product demand, but stronger-than-expected sales in other areas helped Pfizer beat the Street’s estimates.